Recent developments include the publication of intranasal Foralumab clinical study results in peer-reviewed journals, completion of a registered direct offering raising $8.8 million, and ongoing clinical trials in neurodegenerative diseases.

• In January 2026, Tiziana Life Sciences announced the peer-reviewed publication of clinical study results for intranasal Foralumab, indicating progress in its clinical development programs [N1][N2].
• The company completed a best efforts registered direct offering in January 2026, raising gross proceeds of $8.8 million through the sale of 7,040,000 ordinary shares at $1.25 per share, with net proceeds intended to fund Phase 2a clinical trials and general corporate purposes [N3][N4].
• Tiziana continues to advance Phase 2 clinical trials of intranasal Foralumab in secondary progressive multiple sclerosis (SPMS), multiple system atrophy (MSA), and Alzheimer's disease, including the commencement of an open-label extension study in SPMS [S1][N1].
• The company has partnerships to scale up manufacturing of intranasal Foralumab, including with Renaissance Lakewood, supporting clinical and potential commercial supply [N7][N8].

The publication of peer-reviewed clinical study results for intranasal Foralumab and ongoing Phase 2 trials in multiple neurodegenerative indications demonstrate scientific progress and potential therapeutic value. Successful completion of clinical trials and regulatory approvals could enable Tiziana to address significant unmet medical needs in diseases such as SPMS, MSA, and Alzheimer's. The company's ability to raise capital through equity offerings and partnerships supports continued development activities and manufacturing scale-up.

Tiziana faces risks typical of clinical-stage biopharmaceutical companies, including the uncertainty of clinical trial outcomes, regulatory approval challenges, and the need for substantial additional capital. The company has incurred consistent operating losses and has no product revenue, which may pressure liquidity. Delays or failures in clinical development, inability to secure funding, or adverse regulatory decisions could impede progress and impact the company's viability.

Tiziana's moat is centered on its proprietary intranasal Foralumab technology and its clinical development pipeline targeting neurodegenerative diseases, a field with high unmet medical need. The company has established intellectual property rights and collaborations to support manufacturing scale-up. However, as a clinical-stage company without approved products or revenue, its competitive position depends heavily on successful clinical trial outcomes, regulatory approvals, and the ability to secure sufficient funding to advance development and commercialization.

• Clinical Development Risk: The success of Tiziana's product candidates depends on the outcome of ongoing and future clinical trials, which are inherently uncertain and may not demonstrate safety or efficacy.
• Regulatory Approval Risk: Obtaining marketing approval from regulatory authorities involves complex processes with uncertain timing and outcomes, which could delay or prevent commercialization.
• Financial Risk: The company has incurred operating losses and relies on equity financings and other capital raises to fund operations, which may dilute existing shareholders and may not be sufficient to meet future funding needs.
• Manufacturing and Commercialization Risk: Scaling up manufacturing and establishing sales, marketing, and distribution capabilities involve significant costs and operational challenges.
• Intellectual Property Risk: Maintaining and defending patent claims and other intellectual property rights is critical but may be challenged or insufficient to protect competitive advantage.

• Tiziana Life Sciences Ltd is a clinical-stage biopharmaceutical company focused on developing product candidates through preclinical and clinical trials, with no approved products or revenue from product sales as of the latest filings [S1].
• The company has primarily funded operations through equity offerings, convertible loans, and other financings, raising net proceeds of $133.4 million through December 31, 2025 [S1].
• Net losses have been incurred since inception, with a net loss of $18.4 million for the year ended December 31, 2025, and $11.9 million for the year ended December 31, 2024 [S1].
• As of December 31, 2025, cash and cash equivalents were approximately $4.0 million [S1].
• Research and development expenses increased to $10.3 million in 2025 from $5.2 million in 2024, driven by ongoing and new clinical trials for Foralumab in multiple indications including SPMS, MSA, and Alzheimer's disease [S1].
• General and administrative expenses were $10.9 million in 2025, slightly higher than $10.6 million in 2024, reflecting increased payroll and consulting expenses [S1].
• The company completed a best efforts registered direct offering in January 2026, raising gross proceeds of $8.8 million through the sale of 7,040,000 ordinary shares at $1.25 per share, with net proceeds intended to fund Phase 2a clinical trials and general corporate purposes [S1][N3][N4].
• Tiziana's intranasal Foralumab clinical study results were published in a peer-reviewed journal in January 2026, indicating progress in clinical development [N1][N2].
• The company has ongoing clinical trials for Foralumab, including Phase 2 trials in secondary progressive multiple sclerosis (SPMS), multiple system atrophy (MSA), and Alzheimer's disease, with topline data readouts anticipated [S1][N1].
• Tiziana has partnerships to scale up manufacturing of intranasal Foralumab, including with Renaissance Lakewood [N7][N8].
• Liquidity ratios as of December 31, 2024, show a current ratio of 1.02 and a cash ratio of 0.51, indicating near parity of current assets and liabilities [S1].
• The company recognizes risks related to clinical trial outcomes, regulatory approvals, manufacturing scale-up, intellectual property, and commercialization expenses [S1].
• No material legal proceedings are currently pending against the company [S1].